Nutex Health, Inc.
NASDAQ:NUTXMedical - Healthcare Information Services
+$2.84 today
- Market cap
- $1.19B
- Beta
- 2.06
- P/E (TTM)
- 10.4
- EPS (TTM)
- $14.38
Volume 0.16M
Average 0.17M
NUTX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Nutex Health, Inc.NASDAQ: NUTX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $5.49M rose 7.9% year over year, ahead of the +5.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +16.1% a year.
Context
- Depreciation & amortization amounted to 2.3% of revenue in FY2025, down 1.6 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +7.9% holds above the trailing-twelve-month pace of +5.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 20.53M USD
- Year-over-year change
- +8.2%
- 4-year CAGR
- +27.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.53M | +8.2% |
| FY2024 | 2024-12-31 | 18.97M | +7.8% |
| FY2023 | 2023-12-31 | 17.59M | +34.0% |
| FY2022 | 2022-12-31 | 13.13M | +69.2% |
| FY2021 | 2021-12-31 | 7.76M | — |
Depreciation & Amortization vs competitors
How NUTX compares with its peers on the latest reported figures
- NUTX's LTM Mar 2026 depreciation & amortization of $20.93M is the 10th highest of the 11 companies compared; the peer median is $169.89M.
- Its year-over-year change of +5.3% is the 10th highest of 11, against a peer median of +11.1%.
- Depreciation & amortization amounts to 2.4% of revenue for NUTX, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $893M | +9.4% | +0.9% | 4.1% | |
| LTM Mar 2026 | $734M | +85.4% | -1.7% | 3.4% | |
| LTM Jun 2026 | $641.16M | +7.5% | +2.1% | 3.5% | |
| LTM Jun 2026 | $346.5M | +9.8% | +10.4% | 5.6% | |
| LTM Sep 2026 | $177.3M | +18.2% | +15.3% | 5.3% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $162.49M | +10.4% | +4.1% | 2.5% |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $79.99M | +12.4% | +1.0% | 3.4% |
| LTM Mar 2026 | $54.38M | +83.2% | +37.6% | 1.5% | |
| LTM Mar 2026 | $28.51M | +11.8% | +27.6% | 0.5% | |
| LTM Mar 2026 | $20.93M | +5.3% | +16.1% | 2.4% | |
| LTM Mar 2026 | $20.17M | -5.9% | +11.9% | 2.1% | |
| Peer median (excluding NUTX) | $169.89M | +11.1% | +7.2% | 3.4% | |
Competitors are the stored peer set for NUTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 331.53M | 219.29M | 247.65M | 479.95M | 875.26M |
| Cost of Revenue | 152.25M | 203.87M | 212.87M | 283.69M | 430.98M |
| Gross Profit | 179.28M | 15.42M | 34.77M | 196.26M | 444.28M |
| Gross Margin | 54.1% | 7.0% | 14.0% | 40.9% | 50.8% |
| Research & Development | 285.88K | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 5.46M | 20M | 36.07M | 58.56M | 168.66M |
| Operating Expenses | 9.02M | 422.02M | 66.55M | 65.64M | 168.66M |
| Depreciation & Amortization | 7.76M | 13.13M | 17.59M | 18.97M | 20.53M |
| EBITDA | 183.45M | (394.03M) | (14.58M) | 148.65M | 287.54M |
| EBITDA Margin | 55.3% | -179.7% | -5.9% | 31.0% | 32.9% |
| Operating Income | 170.26M | (406.6M) | (31.77M) | 130.62M | 275.63M |
| Operating Margin | 51.4% | -185.4% | -12.8% | 27.2% | 31.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 6.2M | 12.49M | 16.32M | 19.93M | 22.23M |
| Other Income / Expenses | (773.88K) | (13.05M) | (16.72M) | (20.87M) | (30.84M) |
| Income Before Tax | 169.49M | (419.65M) | (48.49M) | 109.75M | 244.78M |
| Pre-Tax Margin | 51.1% | -191.4% | -19.6% | 22.9% | 28.0% |
| Income Tax Expense | 965.73K | 13.09M | (5.07M) | 14.48M | 64.42M |
| Net Income | 132.59M | (424.78M) | (45.79M) | 52.18M | 70.79M |
| Net Margin | 40.0% | -193.7% | -18.5% | 10.9% | 8.1% |
| EPS (Basic) | 33.55 | (100.50) | (10.39) | 10.23 | 11.13 |
| EPS (Diluted) | 33.55 | (100.36) | (10.39) | 9.71 | 10.48 |
| Weighted Avg Shares | 4.02M | 4.23M | 4.41M | 5.1M | 6.36M |
| Weighted Avg Shares (Diluted) | 3.95M | 4.23M | 4.41M | 5.1M | 6.76M |
Nutex Health, Inc.
NASDAQ:NUTX
Intrinsic Alpha fair value
Locked
Current Price
$172.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.